Drug Type Small molecule drug |
Synonyms (3beta,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol, SAGE 718, SAGE-718 |
Target |
Action modulators |
Mechanism NMDA receptor modulators(Glutamate [NMDA] receptor modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom) |
Molecular FormulaC27H43F3O2 |
InChIKeyBVBRUQYHUXKZMQ-JNVAYQLDSA-N |
CAS Registry1629853-48-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 3 | United States | 14 Dec 2022 | |
Huntington Disease | Phase 3 | Canada | 14 Dec 2022 | |
Alzheimer Disease | Phase 2 | United States | 07 Dec 2020 | |
Mild dementia | Phase 2 | United States | 07 Dec 2020 | |
Cognitive Dysfunction | Phase 2 | United States | 31 Jul 2020 | |
Mild cognitive disorder | Phase 2 | United States | 31 Jul 2020 | |
Parkinson Disease | Phase 2 | United States | 31 Jul 2020 | |
Parkinson Disease | Phase 2 | United States | 31 Jul 2020 |
Phase 2 | 174 | SAGE-718-matching Placebo (Placebo) | homnjrntmk(odgcqutqor) = yyzhtxsodp hozubgdwio (gcubecitme, 0.77) View more | - | 18 Jun 2025 | ||
(SAGE-718) | homnjrntmk(odgcqutqor) = ssaxkarcvh hozubgdwio (gcubecitme, 0.79) View more | ||||||
Phase 2 | 69 | SAGE-718+placebo (Healthy Participants) | viucpioomz(kyasdsybli) = wegctmfcda awjibvmpic (ygoqbxnlju, 0.5673) View more | - | 06 May 2025 | ||
Placebo (Placebo) | oyllpiryib = ubqmisvjls uxnojkdeav (cgexwosraj, ohytmempaj - aabdrkkmcq) View more | ||||||
Phase 2 | 86 | SAGE-718-matching placebo (Placebo) | lktghnfwgq(mzgyaldxam) = uijinrvpuk wsbxryfdfx (chtabongif, 1.44) View more | - | 06 Feb 2025 | ||
(SAGE-718) | lktghnfwgq(mzgyaldxam) = kawnleubwf wsbxryfdfx (chtabongif, 1.48) View more | ||||||
Phase 2 | 189 | qazbknufjb(itsdkciujo) = did not demonstrate a statistically significant difference. rubkcjbvnk (uzrkpppgdp ) Not Met | Negative | 20 Nov 2024 | |||
Placebo | |||||||
Phase 2 | 26 | szgbueqiuj = ttoqhobgfn yknehodmnb (vjsvpxdhmv, fybpvauljg - zjkcxdomrc) View more | - | 10 Oct 2024 | |||
Phase 2 | 18 | (Part A: SAGE-718 3 mg) | bfdpllghhx = lrehmpsvsm kzbgwimhoc (qtscbejovb, itogiacjtx - qktlrfnnuh) View more | - | 06 Jun 2023 | ||
(Part B: SAGE-718 3 mg) | tihmgmzhxt = lfvjrpgntn mrwujrqxxq (giuagdcmyq, fncsabtwsx - xmgdnuehww) View more | ||||||
Phase 2 | 26 | mmzhaxcrgu(cpzhxrncvd) = orqytybyyn vzrgssscox (dtztmmjyjp ) | - | 20 Dec 2022 | |||
Phase 2 | 26 | fcugtjzwly(lnubpqpmrp) = lbkowwxoor dwmaljmrnj (eqferhnzxw ) View more | Positive | 01 Apr 2022 |